Discover

LPCN
Lipocine Inc.
2.46
2 x 1.80
2 x 3.03
bid
ask
-
0.10
3.91%
2 @ 04:01 AM
2.41 -0.05 (2.03%)
Ytd-69.36%
1y-22.88%
2.36
day range
2.51
1.81
52 week range
12.37
Open2.50Prev Close2.56Low2.36High2.51Mkt Cap20.28M
Vol72.67KAvg Vol398.11KEPS-1.96P/EN/AForward P/E-3.87
Beta1.19Short Ratio2.80Inst. Own9.96%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1450-d Avg2.30200-d Avg4.661yr Est21.50

LPCN News

benzinga.com
Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26

Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpart

benzinga.com
CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst conse

What's Going On With Carvana Stock Monday?
benzinga.com
What's Going On With Carvana Stock Monday?

BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest anal

What's Going On With Lipocine Stock On Monday?
benzinga.com
What's Going On With Lipocine Stock On Monday?

Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouragin

This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
benzinga.com
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Wall Street analysts changed their outlook on top names. Check out the ratings page for complete cha

Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
benzinga.com
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results

US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
benzinga.com
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results

Nasdaq Down 1%; US Initial Jobless Claims Fall
benzinga.com
Nasdaq Down 1%; US Initial Jobless Claims Fall

US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer d

benzinga.com
Lipocine's LPCN 1154 Misses Phase 3 Primary Endpoint in Postpartum Depression; Shows Early Efficacy

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $15

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises th

benzinga.com
Lipocine Completes Enrollment, Patient Dosing In Its Phase 3 Clinical Study Of LPCN 1154 To Treat Po

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology plat

benzinga.com
Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Ongoing Phase 3 Clin

Company on track to report topline results early in the second quarter of 2026Second planned Data an

benzinga.com
Lipocine Granted U.S. Patent For Hydroxyprogesterone Caproate Compositions And Methods Of Use In Pre

https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZj

benzinga.com
Lipocine Nears Full Enrollment In Phase 3 PPD Trial, Topline Results Expected Q2 2026

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline result

benzinga.com
Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Phase 3 Trial Of LPC

Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, st

benzinga.com
HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers th

benzinga.com
Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst conse

benzinga.com
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

benzinga.com
CORRECTION: Lipocine Q2 EPS $(0.41) Misses $(0.40) Estimate, Sales $622.849K Beat $229.000K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst conse

benzinga.com
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

benzinga.com
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

benzinga.com
Lipocine Says Licensing Partner, Verity Pharma, Files New Drug Submission For TLANDO In Canada

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr

benzinga.com
Lipocine's Licensing Partner, Verity Pharma, Filed A New Drug Submission For Tlando In Canada, Tland

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr

benzinga.com
HC Wainwright & Co. Assumes Lipocine at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Yi Chen assumes Lipocine (NASDAQ:LPCN) with a Buy rating and anno

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com
Lipocine Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $93.86K Miss $370.00K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consens

benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
Lipocine Enters Into License And Supply Agreement With Aché Laboratórios Farmacêuitcos S.A Granting

Lipocine Inc. (NASDAQ:LPCN), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platf

benzinga.com
Lipocine Announces Initiation Of A Phase 3 Trial For LPCN 1154 Which Is In Development For Treatment

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

benzinga.com
Lipocine Announces The Publication And Discussion Of A Manuscript "Oral LPCN 1148 Improves Sarcopeni

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

benzinga.com
Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.44) per share which beat the analyst consens

benzinga.com
Lipocine Announces Distribution And License Agreement With SPC Korea To Commercialize TLANDO In Sout

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

benzinga.com
Lipocine Reports Data From Its qEEG Study Of Its Oral Brexanolone, A Proprietary Bioidentical NAS Be

The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentr

benzinga.com
Lipocine Announces Supply And Distribution Agreement With Pharmalink To Commercialize TLANDO In The

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

benzinga.com
Alliance Global Partners Initiates Coverage On Lipocine with Buy Rating, Announces Price Target of $

Alliance Global Partners analyst Scott Henry initiates coverage on Lipocine (NASDAQ:LPCN) with a

benzinga.com
Lipocine Announces Phase 2 Data On LPCN 2401 To Be Presented At ObesityWeek November 3 – 6, 2024

Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with

benzinga.com
Lipocine Q2 2024 GAAP EPS $(0.56) Beats $(0.78) Estimate, Sales $89.565K Miss $290.000K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.56) per share which beat the analyst consens

benzinga.com
Lipocine Says LPCN 1154 Met standard Bioequivalence (BE) Criteria; Co Says On Track For NDA Filing,

Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞Ctrough criterion was metLPCN 1154

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Co

 Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that Phase 2 results on L

benzinga.com
Lipocine Q1 EPS $0.66 Up From $(0.76) YoY, Sales $7.50M Up From $54.99K YoY

Lipocine (NASDAQ:LPCN) reported quarterly earnings of $0.66 per share. This is a 186.84 percent incr

benzinga.com
Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EA

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154

Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session